NZ709379A - Oral formulation containing tranexamic acid - Google Patents

Oral formulation containing tranexamic acid

Info

Publication number
NZ709379A
NZ709379A NZ709379A NZ70937909A NZ709379A NZ 709379 A NZ709379 A NZ 709379A NZ 709379 A NZ709379 A NZ 709379A NZ 70937909 A NZ70937909 A NZ 70937909A NZ 709379 A NZ709379 A NZ 709379A
Authority
NZ
New Zealand
Prior art keywords
tranexamic acid
oral formulation
formulation containing
containing tranexamic
tooth extraction
Prior art date
Application number
NZ709379A
Inventor
Don Macalister
Original Assignee
Don Macalister
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Don Macalister filed Critical Don Macalister
Priority to NZ709379A priority Critical patent/NZ709379A/en
Publication of NZ709379A publication Critical patent/NZ709379A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided is a topical oral formulation, in the form of a gel, comprising 1 to about 70% tranexamic acid and chlorhexidine, with a viscosity of about 100 to about 15 000 cP. Further provided are uses of the formulation in the manufacture of a medicament for the treatment or prevention of alveolar ostetitis following tooth extraction, or for producing or maintaining a blood clot in a tooth extraction site in a patient to which an anticoagulant has been or is to be, administered, or who suffers from an excessive bleeding disorder.
NZ709379A 2009-12-17 2009-12-17 Oral formulation containing tranexamic acid NZ709379A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ709379A NZ709379A (en) 2009-12-17 2009-12-17 Oral formulation containing tranexamic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ709379A NZ709379A (en) 2009-12-17 2009-12-17 Oral formulation containing tranexamic acid
NZ61918009 2009-12-17

Publications (1)

Publication Number Publication Date
NZ709379A true NZ709379A (en) 2017-03-31

Family

ID=58397946

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ709379A NZ709379A (en) 2009-12-17 2009-12-17 Oral formulation containing tranexamic acid

Country Status (1)

Country Link
NZ (1) NZ709379A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
EA201290171A1 (en) INTRODUCED ORAL CORRECTIC STERILE COMPOSITIONS
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
BR112014031394A2 (en) compositions and methods for transmucosal absorption
BR112013027674A2 (en) "uses of nanoparticle compositions, compositions comprising said nanoparticles and single needle catheter".
BR112014003414A2 (en) method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
NZ604029A (en) Methods of treating bladder cancer
BR112015000136A2 (en) dietary fiber for use in treating a gastrointestinal side effect of a nutrition or medicine
MY173215A (en) Acetylcysteine compositions and methods of use thereof
BR112012027092A2 (en) methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy
BRPI0806392A8 (en) use of aclidinium, aclidinium, treatment or prevention method and pharmaceutical composition
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
SG179027A1 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
NZ608292A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
CA2899775C (en) Compositions and methods for pain relief without numbness
MY190257A (en) Optimised subcutaneous therapeutic agents
MX2014008521A (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers.
RU2009105708A (en) METHOD FOR TREATMENT AND PREVENTION OF DENTAL CARIES AND GINGIVITIS
NZ709379A (en) Oral formulation containing tranexamic acid
BR112012000773A2 (en) METHOD FOR TREATMENT OF AT LEAST ONE CONDITION CHOSEN FROM PAIN, INFLAMMATION AND FEVER IN HUMAN PATIENTS METHOD FOR THE TREATMENT OF AT LEAST ONE CONDITION CHOSEN FROM PAIN, INFLAMMATION AND FEVER IN CRITICALLY ILL PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS
BR112015017546A2 (en) hemostatic compositions, uses thereof and kit
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
Scotti et al. Anti-inflammatory and wound healing effects of an essential oils-based bioadhesive gel after oral mucosa biopsies: Preliminary results
BR112012028153A2 (en) Pharmaceutical composition and method for treating hypertension

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed